Karen Aiach, Lysogene CEO (RE(ACT) Discovery Institute)
Gene therapy flunks PhII/III study, but former Sarepta partner sees a path forward — if it can find the cash
The development path for Lysogene’s gene therapy for MPS IIIA has been a rocky one. After the FDA slapped a partial clinical hold on a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
